Oct 2026· Clinical Interventions in Aging· Vol 21, pp. 1-19· 0 citations· 85 references
Medicine
TL;DR
A narrative review synthesizes empirical evidence from 2016 through 2026 of language impairment in Alzheimer’s disease, highlighting the necessity of biological amyloid and tau biomarker confirmation and prioritizing standardized speech endpoints to assess disease-modifying therapies.
Abstract
Abstract Language impairment is a core clinical manifestation of Alzheimer’s disease (AD) that profoundly affects autonomy, decision-making, and social participation. Building upon the 2015 review by Kuca et al., this narrative review synthesizes empirical evidence from 2016 through 2026. A structured Web of Science Core Collection search retrieved 154 records. Following screening, 66 records were excluded and 88 full-text reports were appraised, of which 13 were consolidated, yielding 75 cited core empirical studies alongside foundational diagnostic, neuropathological, and trial benchmarks. Four main areas are synthesized. First, progressive linguistic decline across clinical stages is characterized, delineating typical amnestic AD dementia, mild cognitive impairment due to AD, and the logopenic variant of primary progressive aphasia (lvPPA), highlighting the necessity of biological amyloid and tau biomarker confirmation. Second, automated speech and natural language processing biomarkers have emerged as scalable tools predicting progression to dementia and detecting biological amyloid-beta positivity; however, real-world translation remains constrained by demographic bias, cross-linguistic variations, acoustic sensitivity, and privacy issues. Third, non-pharmacological interventions, including structured language stimulation and naming therapy, demonstrate measurable task-specific improvements; nevertheless, gains are largely restricted to trained items with minimal transfer to everyday discourse. Caregiver communication training programs reliably improve dyadic interactions and mitigate caregiver distress. Fourth, approved symptomatic drugs do not directly reverse language decline, and add-on memantine in the randomized ROMEO-AD trial produced no statistically significant language benefit over donepezil alone. Disease-modifying anti-amyloid antibodies offer biological intervention for biomarker-positive lvPPA, but pivotal trials lacked primary speech endpoints, establishing eligibility rather than demonstrated language recovery. Non-invasive neuromodulation remains preliminary and requires sham-controlled trials. Communication should be recognized as a distinct clinical outcome in trial designs, prioritizing standardized speech endpoints to assess disease-modifying therapies.
Abstract The field of Alzheimer's disease (AD) research has seen major advances in understanding manifestations of AD‐related neuropsychiatric symptoms (NPS), including recent addition of NPS to the 2024 National Institute of Aging–Alzheimer's Association (NIA‐AA) clinical staging framework. This focused review highlig...
K. Sankhe, Daniella Vellone, Dylan X. Guan et al.· Alzheimer's & Dementia· 0 citations
OBJECTIVES
To explore the cognitive and linguistic impairments associated with Alzheimer's disease (AD) in individuals with Down syndrome (DS), identify gaps in current research, and propose directions for future investigation.
METHODS
A systematic review following PRISMA guidelines was conducted using PubMed, Scopus...
Maximiliano Gaete-Espina, Annais Becerra-Quinteros, Catalina Hermosilla-Navea et al.· Aging & Mental Health· 0 citations
Overall, the pattern of associations varied by biomarker modality, IC domain, and study design, suggesting that AD-related pathology and neurodegeneration have functional correlates beyond cognition.
As our population ages, the prevalence of dementia, including Alzheimer's dementia (AD) and frontotemporal dementia (FTD), is increasing. Early dementia diagnoses facilitate access to interventions when they are most effective for prolonging and improving life. Verbal fluency tests (e.g., FAS and Animal Fluency) can ai...
C. Chang, A. Foran, W.-L. M. Cheung· Neuropsychology Review· 0 citations
Background Mild cognitive impairment (MCI) is a critical transition stage toward Alzheimer’s disease (AD). While standard longitudinal and survival methods evaluate disease progression separately, joint modeling handles their complex interdependencies. However, no systematic review has exclusively evaluated joint model...
A. Mouiha, M. Masrour, M. Zarrouk et al.· Belitung Nursing Journal· 0 citations
Background: Alzheimer’s disease (AD) care is increasingly communication-intensive, requiring sustained caregiver education, symptom monitoring, behavioral management, and coordination across fragmented clinical settings. Large language models (LLMs) can generate, summarize, and adapt natural language at scale, creating...
T. Alkam, E. Tarshizi, A. V. Van Benschoten· Journal of Dementia and Alzh...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.